Vivos Therapeutics (NASDAQ:VVOS) Shares Down 2.9% – Time to Sell?

Vivos Therapeutics, Inc. (NASDAQ:VVOS) dropped 2.9% during trading on Monday . The stock traded as low as $0.4125 and last traded at $0.4196. Approximately 171,717 shares traded hands during mid-day trading, a decline of 82% from the average session volume of 958,266 shares. The stock had previously closed at $0.4320.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. HC Wainwright decreased their price target on Vivos Therapeutics from $7.00 to $2.50 and set a “buy” rating on the stock in a research report on Friday, April 17th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Vivos Therapeutics in a research note on Monday, April 20th. Finally, Ascendiant Capital Markets upped their target price on shares of Vivos Therapeutics from $3.00 to $3.10 and gave the stock a “buy” rating in a report on Thursday, June 4th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $2.80.

Vivos Therapeutics Stock Up 1.3%

The company’s 50-day moving average is $0.58 and its two-hundred day moving average is $1.18. The company has a market capitalization of $5.77 million, a P/E ratio of -0.19 and a beta of 6.16.

Vivos Therapeutics (NASDAQ:VVOS) last announced its earnings results on Wednesday, May 20th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by ($0.07). The company had revenue of $5.14 million for the quarter, compared to the consensus estimate of $4.35 million. Vivos Therapeutics had a negative net margin of 127.70% and a negative return on equity of 2,325.64%. On average, sell-side analysts predict that Vivos Therapeutics, Inc. will post -1.61 EPS for the current year.

Institutional Trading of Vivos Therapeutics

A number of hedge funds have recently made changes to their positions in VVOS. DRW Securities LLC raised its position in Vivos Therapeutics by 179.5% during the fourth quarter. DRW Securities LLC now owns 115,907 shares of the company’s stock valued at $235,000 after purchasing an additional 74,441 shares in the last quarter. Connective Capital Management LLC bought a new stake in Vivos Therapeutics during the third quarter worth about $620,000. B. Riley Wealth Advisors Inc. purchased a new position in shares of Vivos Therapeutics in the 2nd quarter worth about $220,000. XTX Topco Ltd purchased a new position in shares of Vivos Therapeutics in the 2nd quarter worth about $65,000. Finally, Sequoia Financial Advisors LLC bought a new position in shares of Vivos Therapeutics during the 1st quarter valued at about $28,000. 26.35% of the stock is owned by institutional investors.

Vivos Therapeutics Company Profile

Vivos Therapeutics, Inc is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. The company’s proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate forms of sleep-disordered breathing through non-surgical, non-invasive means.

The Vivos System comprises a range of custom oral devices, digital workflow tools, and a structured treatment protocol.